Acute Effect of Lorazepam on Brain Activity Measured by Magnetoencephalograpy (MEG) and Electroencephalography (EEG)
Acute Effect of Four Doses of Lorazepam on Brain Activity Measured by MEG, EEG and the Synchronous Neural Interaction™ Test
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Christina Kay, MA
- Phone Number: 847-981-3570
- Email: christina.kay@abbhh.net
Study Contact Backup
- Name: Donnell Carmichael, PsyD
- Phone Number: 847-981-5771
- Email: donnell.carmichael@abbhh.net
Study Locations
-
-
Illinois
-
Elk Grove Village, Illinois, United States, 60007
- Recruiting
- Alexian Brothers Neurosciences Institute
-
Contact:
- Christina Kay, MA
- Phone Number: 847-981-3570
- Email: christina.kay@abbhh.net
-
Contact:
- Donnell Carmichael, PsyD
- Phone Number: 847-981-5771
- Email: donnell.carmichael@abbhh.net
-
Principal Investigator:
- Concetta Forchetti, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is male between 18 and 35 years of age at the time of screening.
- Subject understands the study procedures and agrees to participate in the study by giving written informed consent.
- Subject is a non-smoker.
- Subject is judged to be in good health based on medical history and brief physical examination and electrocardiogram.
- Subject has normal or corrected to normal visual and auditory acuity.
- Subject agrees to refrain from caffeine 24 hours prior to and then throughout each Study Day.
- Subject agrees to refrain from using alcohol for 48 hours prior to and then throughout each Study Day.
Exclusion Criteria:
- Subject has a diagnosis of a significant neurological condition including Alzheimer's disease, Parkinson's disease, vascular dementia, Lewy body dementia or frontal temporal dementia, human immunodeficiency virus, multiple sclerosis, or severe traumatic brain injury.
- Subject has a history of primary psychotic disorder (e.g. schizophrenia, schizoaffective disorder, delusional disorder) or bipolar disorder.
- Subject has a history of seizures, epilepsy, stroke, peripheral neuropathy, head trauma with persistent post-concussive symptoms, ADHD, dyslexia or other clinically significant neurological disease or cognitive impairment.
- Subject has a lifetime or current history of alcohol or substance abuse/dependence.
- Subject has a history of multiple or severe allergies, or has had an anaphylactic reaction or intolerability to prescription or non-prescription drugs. This includes a documented or subject-verified allergy.
- Subject had an MRI 2 weeks prior to Study Day 2.
- Subject has metal braces or pacemaker that may interfere with the MEG scan.
- Subject is unable to complete the MEG scan procedure.
- The investigator has any concern regarding the safe participation of a subject in the study, or if for any other reason the investigator considers the subject inappropriate for study participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Lorazepam 0.2 mg
All subjects receive lorazepam 0.2 mg in this crossover design.
|
Oral capsule, 0.2 mg, single acute dose
oral capsule, 0.5 mg, single acute dose
oral capsule, 1.0 mg, single acute dose
oral capsule, 2.0 mg, single acute dose
|
|
Experimental: Lorazepam, 0.5 mg
All subjects receive lorazepam 0.5 mg in this crossover design.
|
Oral capsule, 0.2 mg, single acute dose
oral capsule, 0.5 mg, single acute dose
oral capsule, 1.0 mg, single acute dose
oral capsule, 2.0 mg, single acute dose
|
|
Experimental: Lorazepam, 1.0 mg
All subjects receive lorazepam 1.0 mg in this crossover design.
|
Oral capsule, 0.2 mg, single acute dose
oral capsule, 0.5 mg, single acute dose
oral capsule, 1.0 mg, single acute dose
oral capsule, 2.0 mg, single acute dose
|
|
Experimental: Lorazepam, 2.0 mg
All subjects receive lorazepam 2.0 mg in this crossover design
|
Oral capsule, 0.2 mg, single acute dose
oral capsule, 0.5 mg, single acute dose
oral capsule, 1.0 mg, single acute dose
oral capsule, 2.0 mg, single acute dose
|
|
Placebo Comparator: Sugar pill
All subjects receive a sugar pill in this crossover design.
|
oral capsule, single acute dose
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlated Brain Activity using MEG and SNI analysis
Time Frame: 2 hours after dosing with lorazepam
|
The identification and characterization of a pattern of synchronous brain activity that is specifically altered by administration of ascending doses of lorazepam compared to pre-medication baseline and placebo
|
2 hours after dosing with lorazepam
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlated Brain Activity using MEG and standard analyses
Time Frame: 2 hours after dosing with lorazepam
|
Standard frequency-domain analysis of the MEG data to identify and quantify medication-induced changes in signal power in particular frequency bands associated with brain functional activity
|
2 hours after dosing with lorazepam
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Concetta Forchetti, MD, PhD, Alexian Brothers Neurosciences Institute
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Hypnotics and Sedatives
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Anticonvulsants
- Lorazepam
Other Study ID Numbers
Other Study ID Numbers
- ADE-LDR 10-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.